Although my name appears as sole author of the case report referenced in Aschwin's article, I should emphasize that almost all my data about the procedures preceding the transport to Scottsdale were derived from the team leader in this case. This person asked not to be named, for reasons that I can no longer remember. Perhaps (s)he'll be willing to post some clarifications here.
The report that I wrote mentions a "bolus" of perfluorocarbon liquid administered twice to the lungs. This is rather different from repeated cycles of infusion and suction, with perfluorocarbon passing through a heat exchanger. I believe this could not be achieved at the time. Thus it is misleading to suggest that the perfected technology has just been sitting on the shelf since then.
Because I have functioned only as a consultant in the development of liquid ventilation during the past couple of years, I have no authority to write a public update.
Re-reading my own report made me feel embarrassed by the emotional content, yet pleased by the amount of detail. A report of this kind may be unduly subjective, but does give the reader some idea of what actually happened. I regret that no one at Alcor seems to have time to do that these days.